СOMPARING EFFICACY OF mRNA-BASED AND PLASMID VECTORS IN TRANSFECTION OF PERIPHERAL BLOOD LYMPHOCYTES



Cite item

Full Text

Abstract

Adoptive CAR-T cell therapy is an innovative approach in oncology that uses genetically modified
autologous T cells from the patient as a therapeutic tool to fight cancer. The use of DNA plasmids and in vitro transcribed (IVT) mRNA as vectors for the production of CAR-T lymphocytes has a number of advantages compared to viral vectors, such as the absence of cell genome modification, high transfection efficiency, speed and potentially lower cost of obtaining the final product. In current work, we studied the efficiency of transfection (in terms of cell viability and expression of the target protein) of peripheral blood mononuclear cells and cells of transplanted culture (human embryonic kidney cells, HEK293) by electroporation using model DNA plasmid (pmaxGFP) and IVT-mRNA (mRNA-GFP) encoding green fluorescent protein (green fluorescent protein, GFP). The selection of an optimal transfection regimen was performed. It has been shown that although mRNA-GFP yields a comparable number of cells GFP-expressing cells, the cell viability, and, consequently, general efficiency of transfection is significantly higher when using mRNA- GFP as a vector. At the same time, a comparison of expression level by the cells transfected by two techniques showed that the use of mRNA provides more uniform parameters, whereas usage of plasmid vector results in expression levels differing by several orders of magnitude. The changes in expression level were also tested within 7 days after transfection. It was shown that the proportion of GFP-positive cells decreases with time and does not depend on the method of transfection, while the assessment of the proportion of viable cells showed that plasmid transfection leads to a decreased proportion of viable cells after 7 days to 30%, while the use of mRNA practically does not affect viability (the number of viable cells after 7 days did not significantly differ from the control). The results obtained indicate that the usage of IVT-mRNA may be a more preferable tool in production of CAR-T products by electroporation.

About the authors

Yana Yu. Kiseleva

Russian Research Center of Roentgenoradiology, Moscow, Russian Federation

Email: yana.kiseleva@gmail.com
ORCID iD: 0000-0002-8352-4787

PhD, Senior Researcher, Laboratory of Immunology and Oncocytology, Russian Scientific Center of Roentgenoradiology

Russian Federation, 117997 Moscow, Profsoyuznaya str., 86

Alexander M. Shishkin

Russian Research Center of Roentgenoradiology, Moscow, Russian Federation

Email: schy@mail.ru
ORCID iD: 0000-0003-4492-9543

PhD, Senior Researcher, Laboratory of Immunology and Oncocytology, Russian Scientific Center of Roentgenoradiology

Russian Federation, 117997 Moscow, Profsoyuznaya str., 86

Tatyana M. Kulinich

Russian Research Center of Roentgenoradiology, Moscow, Russian Federation

Email: sobral@mail.ru
ORCID iD: 0000-0003-2331-5753

PhD, Head of the Laboratory of Immunology and Oncocytology, Russian Scientific Center of Roentgenoradiology

Russian Federation

Vladimir K. Bozhenko

Russian Research Center of Roentgenoradiology, Moscow, Russian Federation

Author for correspondence.
Email: vbojenko@mail.ru
ORCID iD: 0000-0001-8351-8152

PhD, Doctor of Medical Sciences, Professor, Honored Doctor of the Russian Federation, Head of the Department of Molecular Biology and Experimental Tumor Therapy, Russian Scientific Center of Roentgenoradiology

Russian Federation, 117997 Moscow, Profsoyuznaya str., 86

References

  1. Bonifant C.L. et al. Toxicity and management in CAR T-cell therapy // Molecular Therapy - Oncolytics. 2016. Vol. 3. P. 16011.
  2. Bozhenko V.K. et al. Study of the suppression of a tumor growth expressing a carcinoembryonic antigen with a new high-tech drug carplasmin (CAR-T therapy) in Balb/c nude mice // Usp. mol. onkol. 2023. Vol. 10, № 1. P. 79–86.
  3. Bozza M. et al. A nonviral, nonintegrating DNA nanovector platform for the safe, rapid, and persistent manufacture of recombinant T cells // Sci. Adv. 2021. Vol. 7, № 16. P. eabf1333.
  4. Bulcha J.T. et al. Viral vector platforms within the gene therapy landscape // Sig Transduct Target Ther. 2021. Vol. 6, № 1. P. 53.
  5. Chen W. et al. Path towards mRNA delivery for cancer immunotherapy from bench to bedside // Theranostics. 2024. Vol. 14, № 1. P. 96–115.
  6. Chen Y.-J., Abila B., Mostafa Kamel Y. Car-t: what is next? // Cancers. 2023. Vol. 15, № 3. P. 663.
  7. Cooper L.J.N. et al. Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma // Cytotherapy. 2006. Vol. 8, № 2. P. 105–117.
  8. Corish P., Tyler-Smith C. Attenuation of green fluorescent protein half-life in mammalian cells // Protein Engineering, Design and Selection. 1999. Vol. 12, № 12. P. 1035–1040.
  9. Garfall A.L. et al. Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy // Blood Cancer Discovery. 2023. Vol. 4, № 2. P. 118–133.
  10. Ghilardi G. et al. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy // Nat Med. 2024.
  11. Kenoosh H.A. et al. Recent advances in mRNA-based vaccine for cancer therapy; bench to bedside // ICell Biochem Funct. 2024. Mar;42(2). P.3954
  12. Koppu V. et al. Current Perspectives and Future Prospects of mRNA Vaccines against Viral Diseases: A Brief Review // Int J Mol Cell Med. 2022. Vol. 11, № 3.
  13. Krug C. et al. A GMP-compliant protocol to expand and transfect cancer patient T cells with mRNA encoding a tumor-specific chimeric antigen receptor // Cancer Immunol Immunother. 2014. Vol. 63, № 10. P. 999–1008.
  14. Labbé R.P., Vessillier S., Rafiq Q.A. Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives // Viruses. 2021. Vol. 13, № 8. P. 1528.
  15. Liu C. et al. mRNA-based cancer therapeutics // Nat Rev Cancer. 2023. Vol. 23, № 8. P. 526–543.
  16. Qin S. et al. mRNA-based therapeutics: powerful and versatile tools to combat diseases // Sig Transduct Target Ther. 2022. Vol. 7, № 1. P. 166.
  17. Sayadmanesh A. et al. Strategies for modifying the chimeric antigen receptor (CAR) to improve safety and reduce toxicity in CAR T cell therapy for cancer // International Immunopharmacology. 2023. Vol. 125. P. 111093.
  18. Wang H. et al. Strategies for Reducing Toxicity and Enhancing Efficacy of Chimeric Antigen Receptor T Cell Therapy in Hematological Malignancies // IJMS. 2023. Vol. 24, № 11. P. 9115.
  19. Zhang Z. et al. Optimized DNA electroporation for primary human T cell engineering // BMC Biotechnol. 2018. Vol. 18, № 1. P. 4.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) Kulinich T., Kiseleva Y., Shishkin A., Bozhenko V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № 77 - 11525 от 04.01.2002.